197 related articles for article (PubMed ID: 30840322)
1. Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate.
Mrdenovic S; Zhang Y; Wang R; Yin L; Chu GC; Yin L; Lewis M; Heffer M; Zhau HE; Chung LWK
Cancer; 2019 Jul; 125(13):2222-2232. PubMed ID: 30840322
[TBL] [Abstract][Full Text] [Related]
2. A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models.
Mrdenovic S; Wang Y; Yin L; Chu GC; Ou Y; Lewis MS; Heffer M; Posadas EM; Zhau HE; Chung LWK; Edderkaoui M; Pandol SJ; Wang R; Zhang Y
BMC Cancer; 2023 Jun; 23(1):499. PubMed ID: 37268911
[TBL] [Abstract][Full Text] [Related]
3. Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression.
Kong J; Wang L; Ren L; Yan Y; Cheng Y; Huang Z; Shen F
Toxicol Appl Pharmacol; 2018 Mar; 342():1-13. PubMed ID: 29407771
[TBL] [Abstract][Full Text] [Related]
4. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
[TBL] [Abstract][Full Text] [Related]
5. The Application of Heptamethine Cyanine Dye DZ-1 and Indocyanine Green for Imaging and Targeting in Xenograft Models of Hepatocellular Carcinoma.
Zhang C; Zhao Y; Zhang H; Chen X; Zhao N; Tan D; Zhang H; Shi C
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635650
[TBL] [Abstract][Full Text] [Related]
6. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
7. New Disubstituted Quindoline Derivatives Inhibiting Burkitt's Lymphoma Cell Proliferation by Impeding c-MYC Transcription.
Liu HY; Chen AC; Yin QK; Li Z; Huang SM; Du G; He JH; Zan LP; Wang SK; Xu YH; Tan JH; Ou TM; Li D; Gu LQ; Huang ZS
J Med Chem; 2017 Jul; 60(13):5438-5454. PubMed ID: 28603988
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
[TBL] [Abstract][Full Text] [Related]
9. Curcumin induces apoptosis and inhibits growth of human Burkitt's lymphoma in xenograft mouse model.
Li ZX; Ouyang KQ; Jiang X; Wang D; Hu Y
Mol Cells; 2009 Mar; 27(3):283-9. PubMed ID: 19326074
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate.
Ou Y; Chu GC; Lyu J; Yin L; Lim A; Zhai N; Cui X; Lewis MS; Edderkaoui M; Pandol SJ; Wang R; Zhang Y
Mol Pharm; 2024 Feb; 21(2):873-882. PubMed ID: 38229228
[TBL] [Abstract][Full Text] [Related]
11. Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells.
Yin L; Zhang Y; Yin L; Ou Y; Lewis MS; Wang R; Zhau HE; Zhou Q; Chung LWK
Mol Cancer Ther; 2021 Dec; 20(12):2527-2538. PubMed ID: 34583981
[TBL] [Abstract][Full Text] [Related]
12. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
13. Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB.
Li X; Yang X; Liu Y; Gong N; Yao W; Chen P; Qin J; Jin H; Li J; Chu R; Shan L; Zhang R; Zhang W; Wang H
Clin Cancer Res; 2013 Jun; 19(11):2917-28. PubMed ID: 23620411
[TBL] [Abstract][Full Text] [Related]
14. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.
Barboza NM; Medina DJ; Budak-Alpdogan T; Aracil M; Jimeno JM; Bertino JR; Banerjee D
Cancer Biol Ther; 2012 Jan; 13(2):114-22. PubMed ID: 22336911
[TBL] [Abstract][Full Text] [Related]
15. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
[TBL] [Abstract][Full Text] [Related]
16. Optical imaging of gastric cancer with near-infrared heptamethine carbocyanine fluorescence dyes.
Zhao N; Zhang C; Zhao Y; Bai B; An J; Zhang H; Wu JB; Shi C
Oncotarget; 2016 Aug; 7(35):57277-57289. PubMed ID: 27329598
[TBL] [Abstract][Full Text] [Related]
17. Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor.
Wu JB; Shi C; Chu GC; Xu Q; Zhang Y; Li Q; Yu JS; Zhau HE; Chung LW
Biomaterials; 2015 Oct; 67():1-10. PubMed ID: 26197410
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.
Wehr C; Müller F; Schüler J; Tomann T; Nitschke C; Seismann H; Spillner E; Klingner K; Schneider-Merck T; Binder M; Fiebig HH; Mertelsmann R; Trepel M
Int J Cancer; 2012 Jul; 131(2):E10-20. PubMed ID: 21953178
[TBL] [Abstract][Full Text] [Related]
20. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
